41OLHN Limited

🇸🇬 Singapur Borsası
0.47
SGD
Analysis Scores
Lothien Robustness Score?
78/100
Very Strong
Neden bu skor?
Damodaran ?
60/100
Dalio Risk ?
56/100
Piotroski ?
7/9
Strong
Graham ?
S$0.8
Ucuz
Active Metric?
4/4
Confidence?
72%
Lothien Robustness Summary
88/100
Lothien Sağlamlık: Çok Güçlü (88/100)
Temel göstergelerin büyük çoğunluğu pozitif. Kârlılık, büyüme ve değerleme açısından güçlü görünüm. | Kısa Vade: Olumlu | Uzun Vade: Olumlu | Pozitif: 10 | Negatif: 1 | Nötr: 1
Net Kâr Pozitif
Son çeyrekte S$23M net kâr açıklandı. Şirket kârlı.
Çeyreklik Kâr Artışı
Net kâr bir önceki çeyreğe göre %+352.5 arttı (S$5M → S$23M). Kısa vadede olumlu momentum.
Yıllık Kâr Büyümesi Güçlü
Geçen yılın aynı dönemine göre net kâr %+352.5 arttı. Büyüme trendi sağlıklı.
Hasılat Büyümesi Güçlü
Satış gelirleri çeyreklik %+270.7 arttı (S$33M → S$122M). Talep güçlü.
Yıllık Hasılat Büyümesi Güçlü
Yıllık hasılat %+270.7 arttı. Şirket büyüyor.
Yüksek Net Kâr Marjı
Net kâr marjı %18.6. Her 100S$ satıştan 19S$ kâr kalıyor.
Orta Seviye Borç
Net borç/özkaynak 1.27x. Yönetilebilir seviyede ama takip edilmeli.
Kârlı ama Nakit Üretemiyor
Net kâr pozitif (S$23M) ama FCF negatif (-S$49M). Yatırım harcamaları yüksek veya alacak birikimi var.
FAVÖK Büyümesi
FAVÖK çeyreklik %+179.4 arttı (S$14M → S$38M). Operasyonel verimlilik artıyor.
Çok Düşük F/K
Trailing F/K: 4.7. Piyasa şirketi kârına göre düşük fiyatlıyor. Ucuz görünüyor ama sebebi araştırılmalı.
Defter Değerinin Altında
PD/DD: 0.69. Hisse defter değerinin altında işlem görüyor. Değer tuzağı mı yoksa fırsat mı iyi analiz edilmeli.
Lothien Sağlamlık Skoru: 78/100
Bileşik algoritma değerlendirmesine göre şirketin finansal yapısı güçlü görünüyor.

Data date 2026-10-23 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-10-23
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Orta
252 days
Annual Volatility ?
%30.1
VaR 95% ?
%3.34
daily max loss
VaR 99% ?
%4.63
daily max loss
CVaR 95% ?
%4.41
expected loss (tail)
Max Drawdown ?
%50.0
23.10.2025 → 20.10.2026
Skewness ?
-0.26
Parametrik%3.34
Historik%3.26
Cornish-Fisher%3.40
Return Distribution
Valuation
Potential?
+91.5%
ROIC ?
4.6%
DCF Value ?
6.58
Debt Cycle?
Geç Genişleme
Balance Sheet Analysis? Q2026/6
Son 6 çeyrek ardışık kâr
Fiyat TRAMA-99 altında: %-27.6 — teknik trend olumsuz
Direnç seviyesi: TRAMA-99 = 0.65 SGD
Fundamental & Technical Analysis
Profitability
Net Profit Margin %18.6
Net profit margin %18.6 — at healthy level. Compared to previous quarter +3.4 point increase.
ROE - Return on Equity (TTM) %9.9
ROE %9.9 — low return on equity.
EBITDA Margin %31.2
EBITDA margin %31.2 — operationally very efficient.
Gross Profit Margin %59.1
Gross profit per revenue %59.1. Strong pricing power.
Free Cash Flow Margin (TTM) %-0.6
TTM Free Cash Flow is %-0.6'i. Negative FCF — company consuming cash.
Valuation
P/E Ratio 4.7x Sector: 12.4x
F/K 4.7x — sector median's (12.4x) %62 below. Attractive for value investing.
P/B Ratio 0.69x Sector: 1.49x
PD/DD 0.69x — sector median's (1.49x) well below. Cheap relative to book value.
EV/EBITDA 7.4x Sector: 6.0x
EV/EBITDA 7.4x — sector median's (6.0x) %24 above. Expensive relative to EBITDA.
Indebtedness
Current Ratio 1.80x
Current ratio 1.80x — can comfortably cover short-term debts.
Net Debt / EBITDA 5.5x
Net Debt/EBITDA 5.5x — excessive leverage. Fragile debt profile.
Debt / Equity 1.46x
Debt/Equity 1.46x — moderate financial leverage.
Growth
Revenue Growth (YoY) %+270.7
Revenue YoY %270.7 grew (2026/3) — strong growth. Sector expansion and/or market share increase.
Net Profit Growth (YoY) %+352.5
Net profit YoY %352.5 increased (2026/3) — extraordinary profit growth.
Seasonality Analysis Q1 (Oca-Mar)
Historically strongest quarter: Q1 (Jan-Mar) (avg. profit 13.2M). Weakest quarter: Q2 (Apr-Jun) (avg. profit 8.4M).
Score Explanations
Lothien Robustness
78/100
Very strong robustness score (78/100). Damodaran valuation, Dalio risk analysis and balance sheet quality criteria are largely met.
Very Strong
Potential
+91.5%
Plus %91.5 expected value (0.90) vs current price comparison. 4/4 valuation models could be calculated. Model confidence %72.
Components: PE target: 1.41 | P/B target: 1.09 | EV/EBITDA target: 0.38 | DCF target: 1.41
Damodaran Valuation
60/100
Moderate Damodaran score (60/100). ROIC (%4.6) – WACC (%6.6) difference -2.0 bps. Value creation capacity limited.
Moderate
Dalio Risk Analysis
56/100
Moderate debt risk (56/100). Debt/EBITDA 5.5x — high debt burden.
Leverage: 47/100 | Debt Service: 90/100 | Quality: 82/100
ROIC - Return on Capital
%4.6
ROIC (%4.6) cost of capital (6.6%) below → destroying value.
WACC: %6.6
DCF Discounted Cash Flow
6.58
DCF modeli 6.58 target value produced — compared to current price %1300.7 undervalued.
Current price: 0.47
Debt Cycle Phase
Geç Genişleme
Piotroski F-Score
7/9
Strong Piotroski F-Score (7/9). Profitability, leverage and operational efficiency criteria are largely met.
Strong
Graham Intrinsic Value
S$0.8
Graham intrinsic value: S$0.8. Ucuz
Cheap
⚖️ Sector Comparison
P/E Ratio
4.7x vs 12.4x
Sector median's %62 below — cheap
P/B Ratio
0.69x vs 1.49x
Compared to sector %54 cheaper (by book value)
EV/EBITDA
7.4x vs 6.0x
Compared to sector %24 higher EV/EBITDA
ROIC vs WACC
%4.6 vs %6.6 WACC
ROIC 2.0 bps below cost of capital
Net Profit Margin (TTM)
%17.1 vs %35.8 EBITDA margin
TTM net profit margin %17.1
TRAMA-99 Trend — Strong Downtrend
Price (0.47), TRAMA-99 line's %27.6 below. Significant downtrend. TRAMA line acts as strong technical resistance.
Price:: 0.47
TRAMA: 0.65
Difference: %-27.6
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
P/E Ratio ?
P/B Ratio ?
EBITDA ?
Net Working Capital ?
Current Ratio ?
41O — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.